Table 1.
Subjects characteristics.
| n | Mean ± SEM | |
|---|---|---|
| Gender (M/F), n | 19/34 | – |
| Ethnicity (White; Black; Asian) | 42; 10; 1 | – |
| Age (y) | – | 63.8 ± 0.9 |
| Systolic blood pressure (mm Hg) | – | 130.7 ± 2.9 |
| Diastolic blood pressure (mm Hg) | – | 80.2 ± 1.7 |
| Heart rate (bpm) | – | 69.9 ± 1.7 |
| Medical follow up (y) | – | 10.4 ± 0.9 |
| Drugs | ||
| Atorvastatin (20; 40; 80 mg) | 5; 12; 6 | – |
| Sinvastatin (10; 20; 40 mg) | 1; 16; 13 | – |
| Metformin 500–2550 mg (1–3 daily) | 46a | – |
| Gliclazide 30–120 (1–3 daily) | 12a | – |
| Aspirin (100 mg) | 39 | – |
| Diuretic | 42 | – |
| Angiotensin converting enzyme (ACE) inhibitor | 14 | – |
| Angiotensin II receptor antagonist | 26 | – |
| Beta-blocker | 18 | – |
| Calcium channel blocker | 15 | – |
| Alpha2 adrenergic agonist | 2 | – |
| Vasodilator | 2 | – |
| Antiocoagulant | 2 | – |
| Antiarrhythmic agent | 2 | – |
| Thyroid hormone thyroxine | 7 | – |
| Hyporuricemic agent | 6 | – |
| Proton pump inhibitor | 13 | – |
a
5 subjects were on treatment with both metformin and gliclazide.